Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.75 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | GPR88 | Q9GZN0 | 5/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251658 | 1.00 | CXCR2 (0.75) | CXCR2CXCR1CA12CA1CA2 | |
| SCHEMBL27219474 | 0.87 | CXCR2 (0.73) | CXCR2CXCR1GPR88 | |
| SCHEMBL27219472 | 0.87 | CXCR2 (0.73) | CXCR2CXCR1GPR88 | |
| Ladarixin SCHEMBL253446 | 0.86 | CXCR2 (1.00) | CXCR2CXCR1CA12CA1CA2 | |
| Ladarixin SCHEMBL251618 | 0.86 | CXCR2 (1.00) | CXCR2CXCR1CA12CA1CA2 | |
| SCHEMBL252072 | 0.85 | CXCR2 (0.70) | CXCR2CXCR1CA12CA1CA2 | |
| SCHEMBL252940 | 0.85 | CXCR2 (0.70) | CXCR2CXCR1CA12CA1CA2 | |
| SCHEMBL245190 | 0.84 | CXCR2 (0.69) | CXCR2CXCR1 | |
| SCHEMBL1820095 | 0.84 | CXCR2 (0.69) | CXCR2CXCR1 | |
| SCHEMBL1345636 | 0.84 | CXCR2 (0.69) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293788-B2 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2012-10-23 | — | — | US | disclosed |
| US-20120004264-A1 | 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ PHA.R.MA S.P.A. (IT) | 2012-01-05 | — | — | US | disclosed |
| US-8039656-B2 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2011-10-18 | — | — | US | disclosed |
| EP-1776336-B1 | 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-09-30 | — | — | EP | disclosed |
| US-20090203740-A1 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A (IT) | 2009-08-13 | — | — | US | disclosed |
| EP-1776336-A2 | 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2007-04-25 | — | — | EP | disclosed |
| WO-2005090295-A2 | 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203740-A1 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | CXCR2, CXCR3, MMP8 | CXCR2 1/4885CXCR1 4/4885CA12 2979/4885 |
| US-20120004264-A1 | 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CXCR2, CXCR3, MMP8 | CXCR2 1/4885CXCR1 4/4885CA12 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.